Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC).

Authors

Christine Bestvina

Christine M. Bestvina

University of Chicago, Chicago, IL

Christine M. Bestvina , Dexter Waters , Laura Morrison , Bruno Emond , Marie-Hélène Lafeuille , Annalise Hilts , Patrick Lefebvre , Andy He , Julie Vanderpoel

Organizations

University of Chicago, Chicago, IL, Janssen Scientific Affairs, LLC, Horsham, PA, Analysis Group, Inc., Montreal, QC, Canada

Research Funding

Pharmaceutical/Biotech Company
Janssen Scientific Affairs, LLC

Background: NGS testing for genomic alterations has been found to expedite time to appropriate targeted therapy initiation compared to PCR testing in mNSCLC. This study assessed US payers’ costs of testing, delayed care, and suboptimal treatment initiation for PCR versus NGS testing in patients with mNSCLC. Methods: A decision tree model evaluated testing for guideline-recommended alterations (EGFR, ALK, ROS1, BRAF, KRAS, MET, HER2, RET, NTRK1/2/3) in patients with newly-diagnosed mNSCLC from first test until appropriate therapy initiation using 1) liquid or tissue NGS (60% [90% tissue, 10% liquid] of patients), 2) exclusionary KRAS test followed by sequential PCR tests (5%), 3) sequential PCR tests (5%), or 4) hotspot panel (30%) PCR tests. The proportion of patients testing positive for a targetable alteration and time to appropriate therapy initiation were evaluated. Cost components included genetic testing, testing-related medical services, delayed care (i.e., costs for medical services while waiting for test results), immunotherapy [IO]/chemotherapy [CTX] initiation prior to test results, and suboptimal treatment initiation after test results (i.e., costs of first-line IO/CTX in patients falsely testing negative for an actionable mutation). Results: In a modeled cohort of 1 million members (75% commercial, 25% Medicare), an estimated 1,119 patients had mNSCLC and were tested. The proportion of patients testing positive for a targetable alteration was 45.9% for NGS and 39.4% for PCR testing (Table). Total mean per patient costs were lower for NGS ($8,866) than for PCR ($18,252), driven by more rapid treatment with appropriate therapy (2.1 versus 5.2 weeks), resulting in lower delayed care costs and IO/CTX costs prior to test results. Conclusions: Results suggest that NGS testing may lead to better patient care and reduced costs to the health system relative to PCR testing. Costs of inappropriate IO/CTX initiation are an important component of increased costs of PCR-based approaches.

ResultsNGS
Number tested (N)=671
Sequential
N=56
Exclusionary
N=56
Hotspot Panel
N=336
PCR Approaches Combined*
N=447
Proportion testing positive for a targetable alteration 45.9%37.9%33.1%40.7%39.4%
Proportion initiating suboptimal treatment0.0%8.0%12.8%5.2%6.5%
Time to appropriate therapy initiation, weeks 2.110.510.13.55.2
Total testing-related costs, per patient$8,866$27,939$28,032$15,009$18,252
 Gene testing$4,022$4,669$4,051$6,091$5,659
 Medical$1,245$1,919$1,806$1,250$1,403
 Delayed care$1,301$6,445$6,220$2,155$3,199
 Treatment initiation prior to test results$2,298$12,374$11,901$3,862$5,930
 Suboptimal treatment initiation after test results$0$2,532$4,053$1,651$2,061

*Sum of components differs slightly due to rounding.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research and Quality Improvement

Track

Quality Care/Health Services Research

Sub Track

Value/Cost of Care

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6638)

DOI

10.1200/JCO.2023.41.16_suppl.6638

Abstract #

6638

Poster Bd #

130

Abstract Disclosures

Similar Abstracts

First Author: Alexander Watson

Abstract

2023 ASCO Annual Meeting

Liquid and tissue profiling of targetable co-mutations with KRAS in non-small cell lung cancer.

First Author: Nitesh Rohatgi

First Author: Alissa Jamie Cooper

First Author: Federica Bertolini